It had been shown previously that exogenous administration of FGF21 significantly lowers circulating and intrahepatic triglycerides, reverses fatty liver, and reduces signs of NASH and hepatic fibrosis (23). This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatohepatitis.